Qi Dang

机构：Shandong Tumor Hospital, Shandong First Medical University

发表论文 49 篇 · 总被引 303 次 · h-index 9

代表论文

• The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial (2025 · Nature Medicine · 被引 22)
• OA04.05 SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC) (2024 · Journal of Thoracic Oncology · 被引 16)
• The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. (2024 · Journal of Clinical Oncology · 被引 12)
• TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study (2025 · Cancer Cell · 被引 10)
• Diagnosis and Management of Hemodialysis Access Complications (2025 · JAMA Surgery · 被引 6)
• Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines (2024 · Cancer Immunology Immunotherapy · 被引 6)